China’s mRNA pioneer Stemirna faces post-Covid reinvention test
The biopharma company that led the way in Chinese mRNA research is battling a wave of lawsuits and financial woes, including court limits on its founder’s spending Key Takeaways: Flush…
Recent Articles
RELATED ARTICLES
- Health Guard plans dual listing to fund HPV vaccine fight
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- CHINA BULLETIN: Services, Trade Send Positive Signals
- CHINA BULLETIN: Manufacturing Déjà Vu
- CHINA BULLETIN: Factories Send Mixed Signals
- CHINA BULLETIN: Blinken, Yellen Talk Up China Challenge
Discover hidden China stock gems in our weekly newsletter